Cargando…
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334176/ http://dx.doi.org/10.1186/1546-0096-6-S1-S2 |
| _version_ | 1782230607011512320 |
|---|---|
| author | Ruperto, N Quartier, P Wulffraat, N Woo, P Loy, A Mouy, R Bader-Meunier, B Prakken, B Noseda, E Rordorf, C |
| author_facet | Ruperto, N Quartier, P Wulffraat, N Woo, P Loy, A Mouy, R Bader-Meunier, B Prakken, B Noseda, E Rordorf, C |
| author_sort | Ruperto, N |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3334176 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-33341762012-04-24 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) Ruperto, N Quartier, P Wulffraat, N Woo, P Loy, A Mouy, R Bader-Meunier, B Prakken, B Noseda, E Rordorf, C Pediatr Rheumatol Online J Oral Presentation BioMed Central 2008-09-15 /pmc/articles/PMC3334176/ http://dx.doi.org/10.1186/1546-0096-6-S1-S2 Text en Copyright ©2008 Ruperto et al; licensee BioMed Central Ltd. |
| spellingShingle | Oral Presentation Ruperto, N Quartier, P Wulffraat, N Woo, P Loy, A Mouy, R Bader-Meunier, B Prakken, B Noseda, E Rordorf, C 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| title | 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| title_full | 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| title_fullStr | 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| title_full_unstemmed | 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| title_short | 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| title_sort | 2.2 a phase ii trial with canakinumab, a new il-1beta blocking monoclonal antibody (acz885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic juvenile idiopathic arthritis (sjia) |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334176/ http://dx.doi.org/10.1186/1546-0096-6-S1-S2 |
| work_keys_str_mv | AT ruperton 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT quartierp 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT wulffraatn 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT woop 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT loya 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT mouyr 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT badermeunierb 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT prakkenb 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT nosedae 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT rordorfc 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia AT 22aphaseiitrialwithcanakinumabanewil1betablockingmonoclonalantibodyacz885toevaluatepreliminarydosingsafetyandefficacyprofileinchildrenwithsystemicjuvenileidiopathicarthritissjia |